Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation
- PMID: 23223800
- PMCID: PMC3582386
- DOI: 10.1160/TH12-03-0202
Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation
Abstract
The mechanism underlying a hyperreactive platelet phenotype remains unknown. Since serotonin has been shown to influence platelet biology and atherothrombosis, we sought to investigate the association of platelet serotonin transporter number, binding affinity, and uptake kinetics with platelet aggregation. A total of 542 healthy volunteers had light transmittance platelet aggregometry measured in response to varying concentrations of epinephrine, serotonin, epinephrine plus serotonin, ADP and collagen. Transporter-dependent serotonin uptake rate was determined (Vmax), as were serotonin transporter number (Bmax) and binding affinity (Kd) using 3H paroxetine binding in a homologous displacement assay, nonlinear regression and validated algorithms for kinetic modelling. Stimulation with submaximal (2μM) epinephrine concentration elicited a distinct, bimodal pattern of platelet aggregation in this population. In contrast, subjects exhibited minimal aggregation in response to serotonin alone. Co-stimulation with submaximal epinephrine and serotonin induced platelet aggregation to a level beyond that observed with either agonist alone and maintained a bimodal response distribution. Subjects with heightened (>60%) platelet aggregation to both epinephrine alone and epinephrine plus serotonin exhibited increased platelet serotonin uptake, and transporter number and affinity. In a population of healthy subjects, co-stimulation with submaximal concentrations of epinephrine and serotonin identifies a subset of individuals with a hyperreactive platelet aggregation profile that is associated with changes in platelet serotonin function.
Conflict of interest statement
Redford Williams holds a U.S. patent on the 5HTTLPR L allele as risk marker for CVD in persons exposed to chronic stress. There are no other conflicts of interest to disclose.
Figures



Similar articles
-
Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.Am J Ther. 2010 Nov-Dec;17(6):543-52. doi: 10.1097/MJT.0b013e3181b63f21. Am J Ther. 2010. PMID: 19797939
-
Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism.J Thromb Haemost. 2008 Dec;6(12):2168-74. doi: 10.1111/j.1538-7836.2008.03196.x. Epub 2008 Oct 18. J Thromb Haemost. 2008. PMID: 18983505 Clinical Trial.
-
Removal of extraplatelet Na+ eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombin.Proc Natl Acad Sci U S A. 1983 Sep;80(17):5320-4. doi: 10.1073/pnas.80.17.5320. Proc Natl Acad Sci U S A. 1983. PMID: 6577431 Free PMC article.
-
Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics.Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):7-13. doi: 10.1016/j.pnpbp.2004.08.004. Epub 2004 Nov 4. Prog Neuropsychopharmacol Biol Psychiatry. 2005. PMID: 15610939 Free PMC article.
-
Effects of selective serotonin reuptake inhibitors on platelet functions: a literature review.Curr Opin Hematol. 2025 Jan 1;32(1):22-33. doi: 10.1097/MOH.0000000000000847. Epub 2024 Oct 9. Curr Opin Hematol. 2025. PMID: 39401153 Review.
Cited by
-
Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):280-8. doi: 10.1097/QAI.0b013e31828a292c. J Acquir Immune Defic Syndr. 2013. PMID: 23406976 Free PMC article. Clinical Trial.
-
Intervention of the Nuss Procedure on the Mental Health of Pectus Excavatum Patients.Ann Thorac Cardiovasc Surg. 2017 Aug 20;23(4):175-180. doi: 10.5761/atcs.oa.17-00014. Epub 2017 Jun 16. Ann Thorac Cardiovasc Surg. 2017. PMID: 28626162 Free PMC article.
-
Platelet Function Is Associated With Dementia Risk in the Framingham Heart Study.J Am Heart Assoc. 2022 May 3;11(9):e023918. doi: 10.1161/JAHA.121.023918. Epub 2022 Apr 26. J Am Heart Assoc. 2022. PMID: 35470685 Free PMC article.
-
Effects of clinical depression on left ventricular dysfunction in patients with acute coronary syndrome.J Thromb Thrombolysis. 2021 Apr;51(3):693-700. doi: 10.1007/s11239-020-02268-4. J Thromb Thrombolysis. 2021. PMID: 32876809 Free PMC article.
-
Targeting thrombogenicity and inflammation in chronic HIV infection.Sci Adv. 2019 Jun 12;5(6):eaav5463. doi: 10.1126/sciadv.aav5463. eCollection 2019 Jun. Sci Adv. 2019. PMID: 31206016 Free PMC article. Clinical Trial.
References
-
- Davi G, Patrono C. Platelet activation and atherothrombosis. New Engl J Med. 2007;357:2482–2494. - PubMed
-
- Ruggeri ZM. Platelets in atherothrombosis. Nature Med. 2002;8:1227–1234. - PubMed
-
- Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin Proc. 2006;81:59–68. - PubMed
-
- Elwood PC, Renaud S, Sharp DS, et al. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation. 1991;83:38–44. - PubMed
-
- Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822–1834. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical